Lithium 6-methyl-4,5, 6,7-tetrahydrothieno[2,3-c]-pyridine-2-carboxylate | 365996-56-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 英文名称: Lithium 6-methyl-4,5, 6,7-tetrahydrothieno[2,3-c]-pyridine-2-carboxylate
• 英文别名: Lithium 6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-2-carboxylate；lithium;6-methyl-5,7-dihydro-4H-thieno[2,3-c]pyridine-2-carboxylate
• CAS: 365996-56-1
• 化学式: C₉H₁₀NO₂S*Li
• 分子量: 203.191
• InChiKey: QKNMCTGCCNCGRJ-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -2.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  71.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (1S,2R)-N1-[(5-Chloroindol-2-yl)carbonyl]-1,2-cyclohexanediamine hydrochloride 、 Lithium 6-methyl-4,5, 6,7-tetrahydrothieno[2,3-c]-pyridine-2-carboxylate 生成 (+/-)-cis-N1-[(5-Chloroindol-2-yl)carbonyl]-N2-[(6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl)carbonyl]-1,2-cyclohexanediamine hydrochloride
  参考文献：
  名称：

  ETHYLENEDIAMINE DERIVATIVES

  摘要：

  公开号：

  EP1270557B1
• 作为产物：
  描述：

  6-methyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine 生成 Lithium 6-methyl-4,5, 6,7-tetrahydrothieno[2,3-c]-pyridine-2-carboxylate
  参考文献：
  名称：

  ETHYLENEDIAMINE DERIVATIVES

  摘要：

  公开号：

  EP1270557B1

文献信息

• Ethylenediamine derivatives
  申请人：——

  公开号：US20040122063A1

  公开（公告）日：2004-06-24

  The invention relates a compound represented by the formula (1): Q 1 -Q 2 -C(═O)—N(R 1 )-Q 3 -N(R 2 )-T 1 -Q 4 ( 1 ) wherein R 1 and R 2 represent H or the like; Q 1 represents an aromatic ring, heterocyclic ring or the like; Q 2 represents a single bond, aromatic ring, heterocyclic ring or the like; Q 3 represents a group 1 or the like, Q 4 represents an aromatic ring, heterocyclic ring or the like; and T 1 represents —CO— or —SO 2 —, and a medicine which comprises the compound and is useful for thrombosis and embolism.

  本发明涉及一种由式（1）表示的化合物：Q1-Q2-C(═O)—N(R1)-Q3-N(R2)-T1-Q4(1)，其中R1和R2代表H或类似物；Q1代表芳香环，杂环或类似物；Q2代表单键，芳香环，杂环或类似物；Q3代表群1或类似物，Q4代表芳香环，杂环或类似物；T1代表—CO—或—SO2—，以及包含该化合物并对治疗血栓和栓塞有用的药物。
• Novel ethylenediamine derivatives
  申请人：Nakamoto Yumi

  公开号：US20070129371A1

  公开（公告）日：2007-06-07

  A compound represented by the following formula (1): Q 1 —Q 2 —T o —N(R 1 )—Q 3 —N(R 2 )—T 1 —Q 4 ( 1 ) [wherein, R 1 and R 2 are hydrogen atoms or the like; Q 1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may have a substituent, or the like; Q 2 is a single bond or the like; Q 3 represents the following group: —C(R 3a )(R 4a )—C(R 3b )(R 4b )}m 1 —C(R 3c )(R 4c )}m 2 —C(R 3d )(R 4d )}m 3 —C(R 3e )(R 4e )}m 4 —C (R 3f )(R 4f )— (in which, R 3a to R 4e represent hydrogen or the like); T 0 represents a carbonyl group or the like; and T 1 represents —COCONR— or the like]; or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

  以下化合物公式（1）表示的化合物：Q1-Q2-To-N（R1）-Q3-N（R2）-T1-Q4（1）[其中，R1和R2是氢原子或类似物；Q1是饱和或不饱和的5或6元环烃基，可以具有取代基或类似物；Q2是单键或类似物；Q3表示以下基团：-C（R3a）（R4a）-C（R3b）（R4b）}m1-C（R3c）（R4c）}m2-C（R3d）（R4d）}m3-C（R3e）（R4e）}m4-C（R3f）（R4f）-（其中，R3a到R4e代表氢或类似物）；T0表示羰基基团或类似物；T1表示-COCONR-或类似物]；或其盐，溶剂化合物或N-氧化物。该化合物可用作预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布尔格病、深静脉血栓形成、弥漫性血管内凝血综合征、瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征（SIRS）、多器官功能障碍综合征（MODS）、体外循环期间的血栓形成或采血时的血液凝固。
• NOVEL ETHYLENEDIAMINE DERIVATIVES
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1577302A1

  公开（公告）日：2005-09-21

  A compound represented by the following formula (1):Q1-Q2-To-N(R1)-Q3-N(R2)-T1-Q4 [wherein, R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may have a substituent, or the like; Q2 is a single bond or the like; Q3 represents the following group: -C(R3a)(R4a)-C(R3b)(R4b)}m1-C(R3c)(R4c)}m2-C(R3d)(R4d)}m3-C(R3e)(R4e)}m4-C(R3f)(R4f)- (in which, R3a to R4e represent hydrogen or the like); T0 represents a carbonyl group or the like; and T1 represents -COCONR- or the like]; or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

  下式(1)代表的化合物：Q1-Q2-To-N(R1)-Q3-N(R2)-T1-Q4 [其中，R1 和 R2 是氢原子或类似物；Q1 是饱和或不饱和的 5 或 6 位环烃基团，该基团可具有取代基或类似物；Q2 是单键或类似物；Q3 代表以下基团：-C(R3a)(R4a)-C(R3b)(R4b)}m1-C(R3c)(R4c)}m2-C(R3d)(R4d)}m3-C(R3e)(R4e)}m4-C(R3f)(R4f)-（其中，R3a 至 R4e 代表氢或类似物）；T0 代表羰基或类似物；T1 代表 -COCONR- 或类似物]；或其盐、其溶液或其 N-氧化物。 该化合物可用作脑梗塞、脑栓塞、心肌梗塞、心绞痛、肺梗塞、肺栓塞、布格氏病、深静脉血栓形成、弥散性血管内凝血综合征的预防和/或治疗剂、瓣膜或关节置换术后血栓形成、血管成形术后血栓形成和再闭塞、全身炎症反应综合征（SIRS）、多器官功能障碍综合征（MODS）、体外循环过程中血栓形成或抽血时血液凝固。
• Monoacylated 1,2-diaminocycloalkanes
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP2431370A1

  公开（公告）日：2012-03-21

  Compounds represented by the following general formula (9): The compounds (9) are synthetic intermediates of pharmacologically active products.

  以下通式(9)所代表的化合物： 化合物（9）是药理活性产品的合成中间体。
• US7192968B2
  申请人：——

  公开号：US7192968B2

  公开（公告）日：2007-03-20